Business Context and Reporting Period
Company: Plexus Corp.
Filing Type: Form 10-K (Annual Report)
Period Ended: October 1, 2005
Industry: Electronics Manufacturing Services (EMS)
Overview: Plexus provides product realization services (design, manufacturing, testing, logistics) to OEMs in wireline/networking, wireless infrastructure, medical, industrial/commercial, and defense/security/aerospace sectors. The company operates 18 active facilities across the United States, Asia, Mexico, and Europe. In fiscal 2005, the company reclassified its operating segments from a single business segment to four geographical segments: United States, Asia, Mexico, and Europe.
Key Financial Metrics
| Metric | Fiscal 2005 | Fiscal 2004 | Fiscal 2003 |
|---|---|---|---|
| Net Sales | $1,228.9 million | $1,040.9 million | $807.8 million |
| Gross Profit | $105.7 million | $86.8 million | $53.0 million |
| Gross Margin | 8.6% | 8.3% | 6.6% |
| Operating Income (Loss) | $(9.7) million | $9.2 million | $(71.5) million |
| Net Income (Loss) | $(12.4) million | $(31.6) million | $(68.0) million |
| Diluted EPS | $(0.29) | $(0.74) | $(1.61) |
| Cash Flow from Operations | $82.0 million | $(21.4) million | $(20.0) million |
| Working Capital | $239.4 million | $215.4 million | $210.3 million |
| Total Assets | $600.5 million | $545.7 million | $553.1 million |
| Long-Term Debt & Capital Leases | $22.3 million | $23.2 million | $23.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18% year-over-year, driven by growth in all sectors, particularly wireline/networking and medical. This growth was supported by increased orders from major customers Juniper Networks (19% of sales) and General Electric (12% of sales).
- Restructuring and Impairment Costs: The company recorded $39.2 million in pre-tax restructuring and impairment costs in fiscal 2005, compared to $9.3 million in fiscal 2004. This significant increase was primarily due to:
- Goodwill Impairment: $26.9 million charge, including $16.1 million for UK operations (due to a major medical customer moving production) and $10.8 million for Mexico operations.
- Facility Closures: Costs associated with the closure of the Bothell, Washington facility ($7.5 million in 2005).
- Asset Write-offs: $3.8 million impairment of a shop floor data-collection system.
- Profitability: Despite the 18% revenue increase and improved gross margins, the company reported a net loss of $12.4 million, compared to a loss of $31.6 million in the prior year. The loss was primarily driven by the non-cash impairment charges.
- Cash Flow: Operating cash flow turned positive at $82.0 million, a significant improvement from the $21.4 million outflow in fiscal 2004, aided by better working capital management and increased accounts payable.
Guidance, Outlook, and Risks
- Outlook: Management projects full fiscal 2006 sales growth of approximately 15% to 18%. First-quarter fiscal 2006 sales are expected to range between $315 million and $325 million.
- Capital Expenditures: Expected to be between $30 million and $35 million in fiscal 2006, with a significant portion allocated to Asian operations and the ERP platform.
- Key Risks and Contingencies:
- Customer Concentration: The top 10 customers accounted for 60% of net sales. Loss of major customers (Juniper, GE) could materially impact results.
- UK Operations: Uncertainty remains regarding a significant UK medical customer due to a government investigation (Office of Communication) and the customer's intent to move production to lower-cost locations.
- Accounting Changes: Adoption of SFAS No. 123(R) in fiscal 2006 will require expensing stock-based compensation, estimated to impact results by approximately $0.4 million in fiscal 2006.
- Legal: A lawsuit by the Lemelson Foundation regarding patent infringement remains stayed pending potential Supreme Court review, though lower courts have ruled the patents unenforceable.
Investor Verification Checklist
- Customer Dependency: Verify the stability of contracts with Juniper Networks and General Electric, which together represent 31% of total sales.
- UK Segment Viability: Monitor the status of the UK medical customer investigation and the potential transfer of production out of the UK, which triggered a $16.1 million goodwill impairment.
- Restructuring Execution: Confirm the completion of the Bothell facility closure and the realization of cost savings from the $39.2 million in restructuring charges.
- Working Capital Trends: Assess the sustainability of the improved cash conversion cycle and inventory turnover (6.4x) in the context of projected sales growth.
- Goodwill Balance: Note that remaining goodwill is $7.0 million, entirely tied to UK operations, making future impairment risks concentrated in that region.